MX2022014626A - Un tratamiento de bloqueo de il-1 inhalado para la inmunopatologia de las vias respiratorias. - Google Patents

Un tratamiento de bloqueo de il-1 inhalado para la inmunopatologia de las vias respiratorias.

Info

Publication number
MX2022014626A
MX2022014626A MX2022014626A MX2022014626A MX2022014626A MX 2022014626 A MX2022014626 A MX 2022014626A MX 2022014626 A MX2022014626 A MX 2022014626A MX 2022014626 A MX2022014626 A MX 2022014626A MX 2022014626 A MX2022014626 A MX 2022014626A
Authority
MX
Mexico
Prior art keywords
immunopathology
inhaled
respiratory tract
blockade treatment
inflammatory disorder
Prior art date
Application number
MX2022014626A
Other languages
English (en)
Spanish (es)
Inventor
Michelle Palacios
Lyn A Baranowski
Stephen A Wring
Katelyn R Crizer
Original Assignee
Altavant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altavant Sciences Gmbh filed Critical Altavant Sciences Gmbh
Publication of MX2022014626A publication Critical patent/MX2022014626A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022014626A 2020-05-21 2021-05-20 Un tratamiento de bloqueo de il-1 inhalado para la inmunopatologia de las vias respiratorias. MX2022014626A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063028494P 2020-05-21 2020-05-21
US202063072895P 2020-08-31 2020-08-31
PCT/IB2021/000347 WO2021234457A1 (en) 2020-05-21 2021-05-20 An inhaled il-1 blockade treatment for respiratory tract immunopathology

Publications (1)

Publication Number Publication Date
MX2022014626A true MX2022014626A (es) 2023-02-22

Family

ID=76807913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014626A MX2022014626A (es) 2020-05-21 2021-05-20 Un tratamiento de bloqueo de il-1 inhalado para la inmunopatologia de las vias respiratorias.

Country Status (9)

Country Link
US (1) US20230210768A1 (enExample)
EP (1) EP4153213A1 (enExample)
JP (1) JP2023526536A (enExample)
KR (1) KR20230015397A (enExample)
CN (1) CN116348144A (enExample)
AU (1) AU2021277585A1 (enExample)
CA (1) CA3178404A1 (enExample)
MX (1) MX2022014626A (enExample)
WO (1) WO2021234457A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006636A (es) * 2019-12-02 2022-11-09 Altavant Sciences Gmbh Tratamiento de trastornos de las vías respiratorias bajas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1565620A (zh) * 2003-06-09 2005-01-19 上海复旦张江生物医药股份有限公司 白细胞介素－1受体拮抗剂治疗非典型性肺炎的用途
HUE048024T2 (hu) * 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
MX2022006636A (es) * 2019-12-02 2022-11-09 Altavant Sciences Gmbh Tratamiento de trastornos de las vías respiratorias bajas.

Also Published As

Publication number Publication date
AU2021277585A1 (en) 2022-12-15
WO2021234457A1 (en) 2021-11-25
US20230210768A1 (en) 2023-07-06
JP2023526536A (ja) 2023-06-21
KR20230015397A (ko) 2023-01-31
CN116348144A (zh) 2023-06-27
CA3178404A1 (en) 2021-11-25
EP4153213A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
Carter et al. Effects of hypnotics on obstructive sleep apnea endotypes and severity: novel insights into pathophysiology and treatment
JP6466543B2 (ja) 高濃度の一酸化窒素の投与法
Hårdemark Cedborg et al. Effects of morphine and midazolam on pharyngeal function, airway protection, and coordination of breathing and swallowing in healthy adults
MX2022011111A (es) Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.
CY1122533T1 (el) Ανακινρα για χρηση στην αντιμετωπιση συνδρομου αποφρακτικης βρογχιολιτιδας
EA201590933A1 (ru) Новые перорально биодоступные соединения, модулирующие контроль дыхания, и способы их использования
EA200800905A1 (ru) Агенты, связывающиеся с мишенью в легочной ткани, для лечения респираторных заболеваний
MX2012007813A (es) Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional.
EA201171215A1 (ru) Стоматологическое анестезирующее средство для интраназального введения, содержащее тетракаин и вазоконстриктор
MX2022014626A (es) Un tratamiento de bloqueo de il-1 inhalado para la inmunopatologia de las vias respiratorias.
Tsukamoto et al. Effect of midazolam and butorphanol premedication on inhalant isoflurane anesthesia in mice
SE0400378D0 (sv) Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
Jin et al. Exercise training inhibits macrophage-derived IL-17A-CXCL5-CXCR2 inflammatory axis to attenuate pulmonary fibrosis in mice exposed to silica
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
On et al. Clinical efficacy of a position-responding mandibular advancement device in patients with obstructive sleep apnea
EA202190842A1 (ru) Антагонисты 2-адренорецептора подтипа с (альфа-2с адренорецепторов) для лечения апноэ во сне
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
JOP20210121A1 (ar) عملية لإنتاج أشكال جرعة صيدلانية تحتوي على مثبطات قناة task-1 و task-3، واستخدامها في علاج اضطراب التنفس
MohammadSadeghi et al. Pharmacotherapy for reducing saliva and droplet production in airborne procedures may help to decrease the COVID-19 transmission: A hypothesis
Xu et al. Effects of dexmedetomidine on the recovery profiles from general anesthesia in patients undergoing endoscopic sinus surgery
RU2009141168A (ru) Способы и композиции, содержащие дезвенлафаксин или дулоксетин, для лечения расстройств дыхания во время сна
O'Halloran et al. Clonidine induces upper airway closure in awake goats
US20230052806A1 (en) Methods and apparatuses for delivery of an agent to the lungs and nasal passages
TR2023008875A2 (tr) Pedi̇atri̇k hastalarda kullanilan nazal yüksek akiş kanülleri̇nde yeni̇li̇k